226 related articles for article (PubMed ID: 27533468)
21. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
22. Manipulation of the host translation initiation complex eIF4F by DNA viruses.
Walsh D
Biochem Soc Trans; 2010 Dec; 38(6):1511-6. PubMed ID: 21118117
[TBL] [Abstract][Full Text] [Related]
23. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.
Vujic I; Posch C; Sanlorenzo M; Yen AJ; Tsumura A; Kwong A; Feichtenschlager V; Lai K; Arneson DV; Rappersberger K; Ortiz-Urda SM
Oncotarget; 2014 Sep; 5(17):7936-44. PubMed ID: 25277205
[TBL] [Abstract][Full Text] [Related]
24. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
[TBL] [Abstract][Full Text] [Related]
25. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
26. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
27. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
28. A Preexisting Rare
Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
[TBL] [Abstract][Full Text] [Related]
29. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
Park S; Kim TM; Cho SY; Kim S; Oh Y; Kim M; Keam B; Kim DW; Heo DS
Cancer Lett; 2020 Dec; 495():135-144. PubMed ID: 32979462
[TBL] [Abstract][Full Text] [Related]
30. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
31. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
32. eIF4F: a retrospective.
Merrick WC
J Biol Chem; 2015 Oct; 290(40):24091-9. PubMed ID: 26324716
[TBL] [Abstract][Full Text] [Related]
33. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
34. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.
Shen S; Faouzi S; Bastide A; Martineau S; Malka-Mahieu H; Fu Y; Sun X; Mateus C; Routier E; Roy S; Desaubry L; André F; Eggermont A; David A; Scoazec JY; Vagner S; Robert C
Nat Commun; 2019 Dec; 10(1):5713. PubMed ID: 31844050
[TBL] [Abstract][Full Text] [Related]
35. NRAS
Banik I; Cheng PF; Dooley CM; Travnickova J; Merteroglu M; Dummer R; Patton EE; Busch-Nentwich EM; Levesque MP
Pigment Cell Melanoma Res; 2021 Mar; 34(2):150-162. PubMed ID: 32910840
[TBL] [Abstract][Full Text] [Related]
36. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
[TBL] [Abstract][Full Text] [Related]
38. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
39. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.
Sanlorenzo M; Vujic I; Esteve-Puig R; Lai K; Vujic M; Lin K; Posch C; Dimon M; Moy A; Zekhtser M; Johnston K; Gho D; Ho W; Gajjala A; Oses Prieto J; Burlingame A; Daud A; Rappersberger K; Ortiz-Urda S
Sci Rep; 2018 Jul; 8(1):10902. PubMed ID: 30026510
[TBL] [Abstract][Full Text] [Related]
40. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
